# Cancer Immunotherapy * **Definition:** A type of cancer treatment that uses the body's immune system to fight cancer cells, often leading to improved survival rates for patients. * **Taxonomy:** Healthcare Topics / Cancer Immunotherapy ## News * Selected news on the topic of **Cancer Immunotherapy**, for healthcare technology leaders * 14K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/27/2025 | [**University of Houston receives $3 million to set up a Cancer Immunotherapy Biomarker Core**](https://www.news-medical.net/news/20250527/University-of-Houston-receives-243-million-to-set-up-a-Cancer-Immunotherapy-Biomarker-Core.aspx) | [[News Medical Net]] | | 5/22/2025 | [**New approach to evaluating cases with rheumatic reactions to cancer immunotherapy**](https://medicalxpress.com/news/2025-05-approach-cases-rheumatic-reactions-cancer.html) | [[MedicalXpress]] | | 5/16/2025 | [**OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update**](https://finance.yahoo.com/news/os-therapies-reports-first-quarter-100000519.html) | [[Yahoo Finance]] | | 5/11/2025 | [**Integrating AI-based neoantigen prediction and APC-targeted delivery to enhance cancer immunotherapy**](https://www.bioworld.com/articles/720080-integrating-ai-based-neoantigen-prediction-and-apc-targeted-delivery-to-enhance-cancer-immunotherapy) | [[BioWorld]] | | 4/30/2025 | [**How an Israeli Health System Launched the Nation's First Virtual Hospital Program**](https://www.healthitanswers.net/how-an-israeli-health-system-launched-the-nations-first-virtual-hospital-program/) | [[Health IT Answers]] | | 4/24/2025 | [**Novel cancer immunotherapy approach could complement existing CAR-T treatments**](https://www.news-medical.net/news/20250424/Novel-cancer-immunotherapy-approachcould-complement-existing-CAR-T-treatments.aspx) | [[News Medical Net]] | | 4/23/2025 | [**Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore**](https://www.globenewswire.com/news-release/2025/04/23/3066298/0/en/Akoya-Biosciences-and-Singapore-Translational-Cancer-Consortium-STCC-Partner-on-SUPER-Study-Designed-to-Advance-Cancer-Immunophenotyping-for-Patients-in-Singapore.html) | [[Globe Newswire]] | | 4/15/2025 | [**UVA scientist secures funding to use sound waves for breast cancer therapy**](https://www.news-medical.net/news/20250415/UVA-scientist-secures-funding-to-use-sound-waves-for-breast-cancer-therapy.aspx) | [[News Medical Net]] | | 4/9/2025 | [**OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre ... - Yahoo Finance**](https://finance.yahoo.com/news/os-therapies-completes-acquisition-advaxis-114000244.html) | [[Yahoo Finance]] | | 3/17/2025 | [**The Future of Medicine: How 2025 Became the Year of Medical Breakthroughs - Medium**](https://medium.com/@jordycannon817/the-future-of-medicine-how-2025-became-the-year-of-medical-breakthroughs-7228c6f85a09) | [[Medium]] | | 3/10/2025 | [**New test could predict life-threatening side effects of cancer immunotherapy**](https://www.news-medical.net/news/20250310/New-test-could-predict-life-threatening-side-effects-of-cancer-immunotherapy.aspx) | [[News Medical Net]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of ...**](https://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-Q-tiwWZwkcswR1UZtV7eGe24xL9TZOyQUMS3J72mJlQ7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LOzmn6JePCpHPCiYGaEx4DL1Rq8pNwkf3AarimpDzQGuQ==) | [[Business Wire]] | | 12/31/2024 | [**Precision Medicine Software Market Focused Insights 2024-2029, with Key Player Profiles of Syapse, AccessDX Laboratory, Fabric Genomics, Foundation Medicine, Intel and IBM - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241231013633/en/Precision-Medicine-Software-Market-Focused-Insights-2024-2029-with-Key-Player-Profiles-of-Syapse-AccessDX-Laboratory-Fabric-Genomics-Foundation-Medicine-Intel-and-IBM---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/18/2024 | [**Three for 2025: What you need to know about agentic AI, cancer informatics and data ...**](https://www.healthcareitnews.com/news/three-2025-what-you-need-know-about-agentic-ai-cancer-informatics-and-data-security-imperatives) | [[Healthcare IT News]] | | 12/12/2024 | [**Health IT Business News - December 12, 2024**](https://www.healthitanswers.net/health-it-business-news-december-12-2024/) | [[Health IT Answers]] | | 12/4/2024 | [**Cancer Immunotherapy Drug Discovery Outsourcing Strategic Business Report 2024-2030: Expansion of Targeted Therapy Development Fuels Demand, Rise in Demand for Preclinical Personalized Cancer Models - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20241204468345/en/Cancer-Immunotherapy-Drug-Discovery-Outsourcing-Strategic-Business-Report-2024-2030-Expansion-of-Targeted-Therapy-Development-Fuels-Demand-Rise-in-Demand-for-Preclinical-Personalized-Cancer-Models---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 12/2/2024 | [**Cancer Immunotherapy Drug Discovery Outsourcing Strategic Business Report 2024**](https://finance.yahoo.com/news/cancer-immunotherapy-drug-discovery-outsourcing-123200318.html) | [[Yahoo Finance]] | | 10/16/2024 | [**UCLA and Parker Institute renew alliance to advance cancer immunotherapy**](https://www.news-medical.net/news/20241016/UCLA-and-Parker-Institute-renew-alliance-to-advance-cancer-immunotherapy.aspx) | [[News Medical Net]] | | 8/29/2024 | [**Cancer Immunotherapy Drug Discovery Outsourcing Market Size Expected to Surpass USD ...**](https://www.whatech.com/og/markets-research/medical/873281-cancer-immunotherapy-drug-discovery-outsourcing-market-size-expected-to-surpass-usd-3-16-billion-by-2032.html) | whatech.com | | 8/8/2024 | [**Cancer Immunotherapy Drug Discovery Outsourcing Market Overview And Analysis In The ...**](https://www.whatech.com/og/markets-research/medical/864700-cancer-immunotherapy-drug-discovery-outsourcing-market-overview-and-analysis-in-the-latest-research.html) | whatech.com | | 7/26/2024 | [**Smart Medicine: The Role of AI in Modern Healthcare - GIS user technology news**](https://gisuser.com/2024/07/smart-medicine-the-role-of-ai-in-modern-healthcare/) | gisuser.com | | 7/10/2024 | [**Milwaukee-based experts available during RNC - News - MSOE**](https://www.msoe.edu/about-msoe/news/details/milwaukee-based-experts-available-during-rnc) | msoe.edu | | 6/27/2024 | [**Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors**](http://www.businesswire.com/news/home/20240627634366/en/Calidi-Biotherapeutics-Announces-Appointment-of-Cancer-Immunotherapy-Pioneer-Dr.-George-Peoples-to-Board-of-Directors/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/24/2024 | [**SITC Publishes First Manuscript in JITC Special Series on the Current Challenges and Opportunities in Cancer Immunotherapy**](https://www.prweb.com/releases/sitc-publishes-first-manuscript-in-jitc-special-series-on-the-current-challenges-and-opportunities-in-cancer-immunotherapy-302180435.html) | [[PRWeb]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Parker Institute for Cancer Immunotherapy**: A leading organization in funding and supporting cancer immunotherapy research and clinical trials. - **Parker Institute for Cancer Immunotherapy (PICI)**: A leading organization focused on advancing cancer immunotherapy through research collaborations and innovative treatment strategies. - **Amgen**: A biotechnology company involved in developing cancer immunotherapy treatments. - **Compugen Ltd.**: A clinical-stage company focusing on AI-driven cancer immunotherapy development. - **Thermo Fisher Scientific**: A major player in the cancer immunotherapy drug discovery outsourcing market, providing essential tools and services for research and development. - **Ottimo Pharma**: A startup developing a dual-targeting antibody drug aimed at improving cancer immunotherapy outcomes. - **Microbio Co., Ltd.**: A biotech company focusing on microbiome-based cancer immunotherapy, recently reported promising clinical trial results combining MS-20 and Keytruda. - **AffyImmune Therapeutics**: A biotechnology company focusing on CAR T cell therapy targeting ICAM-1 for solid tumors. - **Laboratory Corporation of America**: Involved in cancer immunotherapy drug discovery, offering laboratory services that support clinical trials and research. - **AstraZeneca**: A pharmaceutical company that focuses on innovative cancer therapies, including immunotherapy. - **Danaher Corporation**: A key company in the cancer immunotherapy sector, focusing on innovative technologies and solutions for drug discovery. - **TuHURA Biosciences**: A company focused on overcoming resistance to cancer immunotherapy with innovative technologies. - **Cure51**: A healthtech startup leveraging AI to analyze genetic and clinical data from cancer survivors to develop new treatment strategies. - **Vironexis Biotherapeutics**: A startup planning to initiate clinical trials for a cancer immunotherapy utilizing an adeno-associated virus to enhance T cell activity. - **BioInvent International AB**: A clinical-stage biotech company developing immune-modulatory antibodies for cancer therapy. - **Fapon Biopharma**: A biopharmaceutical company developing immunocytokines for cancer treatment. - **Pfizer**: A global pharmaceutical corporation engaged in cancer immunotherapy research and development. - **Calidi Biotherapeutics**: A clinical-stage immuno-oncology company utilizing stem cell-based therapies for cancer treatment. - **BostonGene**: A company recognized for its AI-powered platforms that enhance cancer diagnostics and treatment, particularly through multiomics and immune profiling. ### Partnerships and Collaborations - **UCLA and Parker Institute for Cancer Immunotherapy**: Renewed partnership with a $125 million investment to enhance cancer immunotherapy research. - **Virginia Tech Research**: Exploring modifications in biomaterials to enhance cancer treatment efficacy. - **Parker Institute and Penn Medicine**: Renewed partnership with a $125 million investment to enhance cancer immunotherapy research. - **Nomic Bio Inc. and Parker Institute**: Collaborating on large-scale protein profiling to investigate immunotherapy responses in cancer patients. - **Children's Hospital of Philadelphia and Brazilian National Cancer Institute**: Partnering to establish a CAR-T cell production center to enhance access to immunotherapy for pediatric patients in Brazil. - **Nomic Bio Inc. and Parker Institute for Cancer Immunotherapy**: Collaborating to quantify circulating protein biomarkers linked to patient responses to immunotherapy across various cancer types, utilizing Nomic's nELISA platform. - **Microbio Co., Ltd.**: Plans to pursue global collaborations to advance its microbiome-based cancer immunotherapy platform. - **ScaleReady and Wilson Wolf Manufacturing**: Collaboration to support the development of a novel CD8+ TCR-T cell therapy. - **Akoya and STCC**: Collaboration to conduct the SUPER study, aiming to identify biomarkers predicting responses to immune checkpoint inhibitors. - **University of Mississippi Medical Center and Caris Life Sciences**: Joined the Precision Oncology Alliance network to improve cancer treatment. - **Tampa General Hospital and Mass General Brigham**: Enhancing their partnership to launch new medical programs, including CAR-T therapy. - **UC Davis Health and DispatchHealth**: Expanded partnership for same-day, in-home urgent care for cancer patients. - **Bolt Biotherapeutics and Toray Industries**: Joint development of an Immune-Stimulating Antibody Conjugate targeting Caprin-1. - **Boehringer Ingelheim Venture Fund**: Invested in Shenzhen Synthetica to support the development of innovative cancer therapies. - **Guardant Health and MiBA**: This partnership aims to enhance precision medicine through improved biomarker testing and data analytics in cancer care. - **AffyImmune and Dr. Deyaa Adib**: Appointment of Dr. Adib as CMO to lead clinical activities for CAR T cell therapy. - **Lunit and SITC**: Collaboration to provide SITC members access to Lunit SCOPE® IO for advanced tumor analysis. - **Charles River Laboratories and Captain T Cell**: Entered into an agreement for plasmid DNA and retrovirus vector production to support TCR-T cell therapy development. - **Cosmos Health and Professor Trafalis**: Appointment of Professor Trafalis to lead oncology research initiatives, focusing on innovative cancer therapies. - **Flatiron Health and Lifebit Biotech**: Expanding their collaboration into Japan to enhance cancer care through secure access to real-world data. ### Innovations, Trends, and Initiatives - **Anti-TIGIT Antibodies**: Promising advancement in cancer immunotherapy, particularly for solid tumors, with over 50 candidates in clinical trials. - **AT-108 by Asgard Therapeutics**: A new cancer immunotherapy modality that reprograms tumor cells to elicit strong immune responses. - **LAG-3 Targeting**: Research on blocking LAG-3 to enhance T cell activity against cancer cells, contributing to immunotherapy advancements. - **CAR-M Technology**: KRICT's development of CAR-M cells aims to improve efficacy in treating solid tumors, expanding the scope of immunotherapy beyond blood cancers. - **Neoantigen Vaccines**: Emerging treatments targeting unique mutations in cancer cells, utilizing genomic sequencing and AI for personalized therapies. - **Gamma Delta T Cell Therapies**: Innovative immunotherapies showing promise for cancer treatment, with ongoing research and development. - **AI in Immunotherapy**: The development of AI-based models like SCORPIO to predict patient responses to immune checkpoint inhibitors using routine blood tests, enhancing patient selection for treatments. - **mRNA Vaccines**: Gained prominence during the COVID-19 pandemic, showing potential for cancer immunotherapy by targeting unique neoantigens from tumor-specific mutations. - **AI in Cancer Care**: AI technologies are being integrated into cancer diagnostics and treatment planning, enhancing personalized medicine. - **Physical Biomaterials Research**: Investigating how physical characteristics of biomaterials can improve immune responses in cancer treatments. - **Subcutaneous Immunotherapies**: The introduction of subcutaneous formulations like Tecentriq Hybreza is expected to enhance treatment efficiency and improve patient experience. - **Immunocytokine FP008**: Fapon Biopharma's bifunctional anti-PD-1/IL-10M fusion protein targeting resistant cancer populations, showing promising preclinical results. - **Precision Medicine**: Advancements in genomics and AI are enabling personalized treatment strategies, particularly in oncology. - **Extracellular Vesicles for Immunotherapy**: NUS Medicine developed a novel delivery platform using modified nano-sized extracellular vesicles to enhance immunotherapy effectiveness. - **CAR-T Cell Therapy**: The market is experiencing growth due to increasing product approvals and innovations in genetic modifications using CRISPR/Cas9. - **Microbiome-based Therapies**: Emerging as a significant area of research, with companies like Microbio developing therapies that modulate gut microbiota to enhance immunotherapy. - **mRNA Therapy Optimization**: Broad Institute researchers developed a method to optimize mRNA therapies, enhancing protein production for cancer treatment. - **AI in Oncology**: Artificial intelligence is transforming drug development, improving therapeutic identification and reducing approval times. - **Needle-Free Delivery Technologies**: PharmaJet's advancements in needle-free delivery systems aim to improve the immunogenicity of cancer vaccines. - **Predictive Biomarkers for ICANS**: Development of biomarkers to predict neurotoxicity in patients undergoing immunotherapy. ### Challenges and Concerns - **Complexity of Cancer**: The adaptability of cancer cells poses challenges in developing effective immunotherapy strategies. - **Resistance to Immunotherapy**: Addressing primary resistance to checkpoint inhibitors remains a significant challenge in cancer treatment. - **Myocarditis from Immune Checkpoint Inhibitors**: A serious complication affecting 1% of patients, necessitating targeted therapies for safe cancer treatment. - **Immune-Related Side Effects**: Immunotherapy effectiveness is often limited by side effects that can harm healthy tissues, necessitating innovative delivery methods. - **Regulatory Hurdles**: The approval process and time-to-market for new therapies can significantly impact the development of cancer immunotherapies. - **Efficacy of New Treatments**: Recent failures in clinical trials, such as Roche's tiragolumab, raise concerns about the efficacy of new immunotherapy agents and the need for robust validation. - **Limited Patient Response**: Only about 20% of patients respond positively to current immunotherapy treatments, highlighting the need for further research. - **Treatment Resistance**: Understanding the mechanisms of treatment resistance in immunotherapy remains a significant challenge, necessitating ongoing research and innovative solutions. - **Accessibility and Affordability**: High costs of innovative treatments like checkpoint inhibitors raise concerns about patient access. - **Myocarditis Risks**: Research indicates that immune checkpoint inhibitors can lead to myocarditis, highlighting the need for targeted therapies to manage this serious side effect. - **Therapy Resistance**: Emerging resistance to existing therapies, prompting the need for innovative approaches like trispecific antibodies. - **High Costs**: The high costs associated with CAR-T therapies and other advanced treatments pose a barrier to widespread adoption. - **Data Privacy and Bias**: Challenges in AI implementation in oncology include data bias and privacy concerns. - **Healthcare Workforce Shortages**: The oncology sector faces a significant shortage of trained professionals, impacting patient care and treatment outcomes. - **Access to Clinical Trials**: Despite advancements, there are ongoing challenges in patient recruitment and data collection for clinical trials. - **Data Interoperability**: Issues with data sharing and interoperability among healthcare systems complicate the implementation of precision medicine. - **Regulatory Compliance**: The complexity of regulatory approval processes poses challenges for AI technologies in drug development. ## Related Topics [[Cancer Therapy]]; [[Cancer Treatment]]